CANBRIDGE-B (01228) plans to appoint Qingdao Baheal Medical INC. as its exclusive contract sales organization to promote several products of the group.

CANBRIDGE-B(01228) announced on August 11, 2025, that two subsidiaries of the group have officially established a strategic cooperation relationship with a subsidiary of Qingdao Baheal Medical INC. (301015.SZ)(Qingdao Baheal Medical INC.). The parties have entered into a strategic cooperation and exclusive commercial services agreement, whereby the relevant subsidiaries have agreed to appoint the subsidiary of Baheal as the exclusive Contract Sales Organization (CSO) to promote several products of the group in Mainland China, Hong Kong, and Macau (the relevant regions), subject to the limitations of upstream authorization agreements between the group's related member companies and the respective licensors of the products (including, where applicable, the consent of the relevant licensors). The commercial services agreement also stipulates that Baheal's affiliated companies may serve as distributors of the products in the relevant regions at Baheal's discretion.